STING Inhibitors
The Stimulator of Interferon Genes (STING) is a critical adaptor protein in the innate immune system that mediates the response to cytosolic DNA. The pathway is initiated when the enzyme cyclic GMP-AMP synthase (cGAS) detects double-stranded DNA in the cytosol—a signal typically associated with viral or bacterial infection, or cellular damage. Upon binding DNA, cGAS produces the second messenger cyclic GMP-AMP (cGAMP), which then binds to and activates STING, located on the endoplasmic reticulum membrane. Activated STING undergoes a conformational change and translocates to the Golgi apparatus, where it recruits and activates TANK-binding kinase 1 (TBK1). This leads to the phosphorylation and activation of interferon regulatory factor 3 (IRF3) and NF-kappaB, ultimately triggering the production of Type I interferons and other pro-inflammatory cytokines. While STING agonists are being developed to enhance anti-tumor immunity, STING inhibitors are sought for treating a variety of autoimmune and autoinflammatory diseases. Overactivation of the cGAS-STING pathway is a primary driver of conditions such as Aicardi-Goutières Syndrome (AGS), STING-associated vasculopathy with onset in infancy (SAVI), and systemic lupus erythematosus (SLE).
It is also implicated in the chronic inflammation associated with aging (inflammaging) and certain neurodegenerative diseases like Parkinson’s, where mitochondrial DNA leakage can trigger the pathway. Research progress in the development of STING inhibitors has accelerated in recent years. Early inhibitors were often non-specific or had poor pharmacological properties. However, the discovery of covalent inhibitors like H-151 and C-176 represented a major breakthrough. These small molecules bind to the highly conserved Cys91 residue of STING, preventing the palmitoylation required for its activation and translocation. Other classes of inhibitors include those that compete with cGAMP for the cyclic dinucleotide (CDN) binding pocket or those that prevent the recruitment of TBK1. Several pharmaceutical companies are now advancing STING inhibitors into Phase I clinical trials for inflammatory indications.
Inhibitors can be classified by their binding site (CDN-binding site vs. transmembrane domain) and their mode of action (covalent vs. non-covalent). A significant challenge in the field is the high degree of structural polymorphism in human STING, which can affect inhibitor potency across different populations. Furthermore, because STING is essential for host defense against pathogens, there is a risk that chronic inhibition could increase susceptibility to viral infections. Another hurdle is the species-specific differences between mouse and human STING, which can complicate the translation of preclinical findings. Current research is focused on developing highly selective, orally bioavailable inhibitors with favorable safety profiles and exploring their potential in a wide range of conditions, from rare genetic interferonopathies to more common diseases like non-alcoholic steatohepatitis (NASH) and myocardial infarction.
